Diasorin SpA Sees Q4 Revenue of $300M and EPS of $0.81
Diasorin SpA will report Q4 2025 results on March 20 with analysts forecasting $0.30 billion in revenue and $0.81 EPS, and full-year projections of $1.20 billion and $3.40 per share. Over the past 90 days, 2025 revenue estimates fell from $1.21 billion to $1.20 billion and EPS forecasts eased from $3.41 to $3.40.
1. Earnings Release Preview
Diasorin SpA is scheduled to report its Q4 2025 earnings on March 20, with consensus forecasts of $0.30 billion in revenue and $0.81 per share in earnings. For the full year, analysts project $1.20 billion in sales and $3.40 in EPS, reflecting modest growth expectations.
2. Estimate Revisions
In the last 90 days, full-year 2025 revenue estimates for Diasorin have declined from $1.21 billion to $1.20 billion, while EPS forecasts slipped from $3.41 to $3.40. Similar downward adjustments occurred for 2026, with revenue estimates easing from $1.29 billion to $1.27 billion and EPS projections falling from $4.05 to $3.94.
3. Previous Quarter Performance
In Q3 2025, Diasorin reported $0.28 billion in revenue, missing the $0.29 billion consensus by 4.1%, and delivered $0.68 in EPS, below the $0.83 estimate by 17.7%. The stock declined roughly 2.8% following the announcement.
4. Analyst Price Targets and Ratings
Analysts’ one-year average target price for Diasorin stands at $81.56, with a high of $105.00 and a low of $60.00, implying about 28% upside from current levels. The consensus GF Value estimate is $107.96, suggesting nearly 70% upside, and the average brokerage recommendation of 2.4 denotes an Outperform rating.